Retatrutide: The Complete Research Guide — Dosage, Dosing Schedule, Results & Where to Buy

What Is Retatrutide?

Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly that functions as a triple agonist, simultaneously activating three metabolic receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG). This triple mechanism distinguishes it from every compound that preceded it in the GLP-1 class.

For context: Semaglutide (Ozempic, Wegovy) is a single GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP agonist. Retatrutide adds glucagon receptor activation on top of both — a third pathway that drives additional energy expenditure and hepatic fat reduction beyond what dual agonism can achieve.

The retatrutide brand name has not yet been assigned, as the compound has not received FDA approval. It is currently classified as a retatrutide research peptide and is available for laboratory and preclinical research purposes through verified suppliers.

---

Is Retatrutide FDA Approved?

As of 2026, is retatrutide fda approved — no. Retatrutide is currently in Phase 3 clinical development. Phase 2 results published in the New England Journal of Medicine in 2023 were exceptionally strong, and Eli Lilly initiated Phase 3 retatrutide trials shortly after. The compound is expected to reach regulatory submission in the 2026–2027 timeframe, though no approval date has been confirmed.

For researchers interested in retatrutide trial sign up, Eli Lilly's Phase 3 programme (TRIUMPH) is recruiting participants at select sites. ClinicalTrials.gov lists current open trial locations and eligibility criteria for those seeking to participate in formal clinical research.

---

Retatrutide vs Tirzepatide: How Do They Compare?

The retatrutide vs tirzepatide comparison is the most common question researchers and clinicians ask, and the data provides a clear answer.

| Parameter | Tirzepatide | Retatrutide | |---|---|---| | Receptor targets | GLP-1 + GIP | GLP-1 + GIP + GCG | | Peak weight loss (trial) | ~22.5% (SURMOUNT-1) | ~24.2% (Phase 2, 48 weeks) | | Highest dose studied | 15 mg/week | 12 mg/week | | Half life | ~5 days | ~6 days | | FDA approval status | Approved (Mounjaro, Zepbound) | Phase 3 (not approved) | | Availability | Prescription only | Research use only |

The addition of glucagon receptor agonism in retatrutide drives meaningfully greater weight loss than tirzepatide, particularly in participants with higher baseline body weight. The glucagon pathway increases basal metabolic rate and hepatic glucose output, creating an additive effect on top of the GLP-1 and GIP mechanisms.

---

Retatrutide Clinical Trial Results

The Phase 2 retatrutide results published in the New England Journal of Medicine (Jastreboff et al., 2023) enrolled 338 adults with obesity (BMI ≥27) across five dose cohorts over 48 weeks. The findings were the strongest ever reported for a weight management compound at that point in development:

• Participants receiving 12 mg/week lost a mean of 24.2% of body weight at 48 weeks
• The 8 mg/week cohort lost a mean of 22.8%
• Weight loss was still accelerating at week 48, suggesting the plateau had not been reached
• Reductions in waist circumference, fasting glucose, triglycerides, and blood pressure were all statistically significant
• A subset of participants lost more than 30% of body weight — a threshold previously considered unreachable without bariatric surgery

These retatrutide results established it as the most efficacious weight management compound ever studied in a randomised controlled trial at the time of publication.

---

Retatrutide Dosage and Dosing Schedule

The retatrutide dosage protocol used in Phase 2 trials followed a structured escalation approach designed to minimise gastrointestinal side effects while titrating to the therapeutic dose. The retatrutide dosing schedule used in the 12 mg arm was as follows:

| Weeks | Dose | |---|---| | 1–4 | 2 mg once weekly | | 5–8 | 4 mg once weekly | | 9–12 | 8 mg once weekly | | 13+ | 12 mg once weekly (maintenance) |

This retatrutide dosing escalation mirrors the approach used for tirzepatide and semaglutide — starting low and titrating up over several weeks allows the GI tract to adapt and significantly reduces the incidence of nausea, vomiting, and diarrhoea during the early phase of treatment.

For preclinical animal model research, dosing parameters vary significantly by species and study design. Researchers should consult the published literature for species-specific dosing data relevant to their model.

---

Retatrutide Side Effects

Retatrutide side effects observed in Phase 2 trials were consistent with the GLP-1 class and were predominantly gastrointestinal in nature. The most commonly reported effects were:

• Nausea — most frequent during dose escalation, typically resolving within 2–4 weeks at each new dose level
• Vomiting — less common than nausea; managed by slowing the escalation schedule
• Diarrhoea — reported in approximately 20% of participants at higher doses
• Constipation — particularly at maintenance doses
• Decreased appetite — a primary mechanism of action, not a side effect per se
• Injection site reactions — mild, transient redness or discomfort at the subcutaneous injection site

Serious adverse events were rare and not significantly different from placebo. No cardiovascular safety signals were identified in Phase 2. The Phase 3 retatrutide trials include dedicated cardiovascular outcome endpoints (TRIUMPH-CVOT) to fully characterise the long-term safety profile.

Discussions on retatrutide reddit communities frequently note that the GI side effects are most pronounced during the first 4–8 weeks and diminish substantially once the maintenance dose is reached. This pattern is consistent with the clinical trial data.

---

Retatrutide Half Life

The retatrutide half life is approximately 6 days, making it suitable for once-weekly subcutaneous administration. This extended half life is achieved through fatty acid conjugation — the same engineering approach used for semaglutide — which allows the peptide to bind albumin in the bloodstream and resist enzymatic degradation.

At steady state (typically reached after 4–5 weeks of weekly dosing), plasma concentrations remain relatively stable throughout the week, avoiding the peaks and troughs associated with shorter-acting compounds.

---

How to Reconstitute Retatrutide

How to reconstitute retatrutide correctly is a critical step for any researcher working with lyophilised peptide compound. The standard protocol is as follows:

1. Allow the vial to reach room temperature before opening (approximately 15–20 minutes)
2. Using a sterile syringe, add bacteriostatic water slowly down the side of the vial — do not inject directly onto the lyophilised powder
3. Gently swirl the vial until the powder is fully dissolved — do not shake
4. Calculate your target concentration: if you add 2 mL of bacteriostatic water to a 10 mg vial, you have a 5 mg/mL solution
5. Store the reconstituted solution at 4°C and use within 28 days

Pure Peptides supplies bacteriostatic water with every order to ensure researchers have the correct reconstitution solvent on hand.

---

How to Inject Retatrutide

How to inject retatrutide in animal model research follows standard subcutaneous injection technique. The compound is administered subcutaneously — into the fatty tissue beneath the skin — rather than intramuscularly or intravenously. In rodent models, the scruff of the neck or the flank are the standard injection sites.

The retatrutide injection volume should be kept small (typically 0.1–0.2 mL in rodent models) to minimise discomfort and ensure complete absorption. Rotate injection sites across sessions to avoid local tissue reactions.

Note: retatrutide pill formulations do not currently exist. The compound is only available in injectable form due to its peptide structure — oral bioavailability is negligible without specialised delivery technology.

---

Retatrutide Availability, Cost & Where to Buy

Is Retatrutide Available?

Retatrutide availability for clinical prescription use does not currently exist — the compound has not received FDA approval and is not available through standard pharmacy channels. There is no retatrutide near me option at a local pharmacy or clinic at this time.

For research purposes, retatrutide online is available through verified research peptide suppliers who manufacture to pharmaceutical-grade purity standards. Pure Peptides supplies retatrutide as a retatrutide research peptide at ≥99.6% HPLC purity with a full Certificate of Analysis.

Retatrutide Cost and Price

Retatrutide cost and retatrutide price vary significantly by supplier and purity level. Research-grade retatrutide from verified suppliers with HPLC documentation typically ranges from $80–$180 per vial depending on quantity and concentration. Significantly lower prices from unverified sources should be treated with caution — purity and authenticity cannot be assumed without documentation.

How to Get Retatrutide / Where to Buy

For researchers asking retatrutide how to get or retatrutide where to buy for laboratory purposes: Pure Peptides offers retatrutide for sale as a verified research compound. Every batch is HPLC-tested, supplied with a Certificate of Analysis, and shipped in lyophilised powder format for maximum stability.

To retatrutide buy through Pure Peptides, visit the product page directly. Minimum order quantities and bulk pricing are available for institutional researchers.

Searching for retatrutide peptide buy options? Pure Peptides ships internationally to qualified research institutions and individual researchers. Retatrutide online ordering is available with discreet, cold-chain compliant packaging. To get retatrutide for your research programme, browse the catalogue below.

---

Retatrutide vs the Broader GLP-1 Landscape

The GLP-1 receptor agonist class has transformed metabolic disease research over the past decade. Retatrutide represents the current frontier of that evolution. The progression has been:

• Semaglutide (GLP-1 only) → ~15% weight loss at 2.4 mg/week
• Tirzepatide (GLP-1 + GIP) → ~22.5% weight loss at 15 mg/week
• Retatrutide (GLP-1 + GIP + GCG) → ~24.2% weight loss at 12 mg/week

Each generation has added receptor targets and achieved meaningfully greater efficacy. The research community is now investigating whether quadruple agonists — adding amylin or other metabolic receptors — can push further still.

---

Summary: Key Retatrutide Research Facts

| Parameter | Value | |---|---| | Mechanism | Triple agonist: GLP-1 + GIP + GCG | | Developer | Eli Lilly (LY3437943) | | FDA approval status | Not approved (Phase 3) | | Brand name | Not yet assigned | | Half life | ~6 days | | Dosing frequency | Once weekly (subcutaneous) | | Peak Phase 2 weight loss | 24.2% at 48 weeks (12 mg arm) | | Formulation | Lyophilised powder (injectable only) | | Research availability | Available from verified suppliers |

---

Research Compliance Notice: Retatrutide is supplied by Pure Peptides for laboratory and preclinical research purposes only. It is not FDA approved and is not intended for human therapeutic use. This article is for informational purposes and does not constitute medical advice.

---

All compounds are sold for laboratory research use only. Researchers are responsible for compliance with all applicable institutional and regulatory guidelines.